168 related articles for article (PubMed ID: 36271558)
1. Critical assessment of the revised guidelines for vancomycin therapeutic drug monitoring.
Aljutayli A; Thirion DJG; Nekka F
Biomed Pharmacother; 2022 Nov; 155():113777. PubMed ID: 36271558
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic equations versus Bayesian guided vancomycin monitoring: Pharmacokinetic model and model-informed precision dosing trial simulations.
Aljutayli A; Thirion DJG; Bonnefois G; Nekka F
Clin Transl Sci; 2022 Apr; 15(4):942-953. PubMed ID: 35170243
[TBL] [Abstract][Full Text] [Related]
3. Vancomycin area under the curves estimated with pharmacokinetic equations using trough-only data.
Fewel N
J Clin Pharm Ther; 2021 Oct; 46(5):1426-1432. PubMed ID: 34169543
[TBL] [Abstract][Full Text] [Related]
4. Cost comparison of AUC:MIC- versus trough-based vancomycin monitoring for MRSA bacteremia.
Beccari MV; Seabury RW; Mogle BT; Kufel WD; Miller CD; Steele JM
J Am Pharm Assoc (2003); 2020; 60(5):729-733. PubMed ID: 32224054
[TBL] [Abstract][Full Text] [Related]
5. Conversion from Vancomycin Trough Concentration-Guided Dosing to Area Under the Curve-Guided Dosing Using Two Sample Measurements in Adults: Implementation at an Academic Medical Center.
Meng L; Wong T; Huang S; Mui E; Nguyen V; Espinosa G; Desai J; Holubar M; Deresinski S
Pharmacotherapy; 2019 Apr; 39(4):433-442. PubMed ID: 30739349
[TBL] [Abstract][Full Text] [Related]
6. Innovative approaches to optimizing the delivery of vancomycin in individual patients.
Pai MP; Neely M; Rodvold KA; Lodise TP
Adv Drug Deliv Rev; 2014 Nov; 77():50-7. PubMed ID: 24910345
[TBL] [Abstract][Full Text] [Related]
7. Vancomycin: An analysis and evaluation of eight population pharmacokinetic models for clinical application in general adult population.
Duong A; El Gamal A; Bilodeau V; Huot J; Delorme C; Poudrette J; Crevier B; Marsot A
Pharmacotherapy; 2024 Jun; 44(6):425-434. PubMed ID: 38803279
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Vancomycin Area Under the Concentration-Time Curve Predictive Performance Using Bayesian Modeling Software With and Without Peak Concentration: An Academic Hospital Experience for Adult Patients Without Renal Impairment.
Kim HK; Jeong TD
Ann Lab Med; 2023 Nov; 43(6):554-564. PubMed ID: 37387488
[TBL] [Abstract][Full Text] [Related]
9. Vancomycin therapeutic monitoring by measured trough concentration versus Bayesian-derived area under the curve in critically ill patients with cancer.
AbuSara AK; Abdelrahman DH; Habash KI; Al-Shaer MH; Le J; Nazer LH
Pharmacol Res Perspect; 2022 Feb; 10(1):e00912. PubMed ID: 34990089
[TBL] [Abstract][Full Text] [Related]
10. Does calculation method matter for targeting vancomycin area under the curve?
Chang J; Patel D; Vega A; Claeys KC; Heil EL; Scheetz MH
J Antimicrob Chemother; 2022 Jul; 77(8):2245-2250. PubMed ID: 35640658
[TBL] [Abstract][Full Text] [Related]
11. Should the trough concentration of vancomycin be abandoned in therapeutic drug monitoring? A multicentre, retrospective study of critically ill patients without any form of dialysis.
Yu Z; Liu J; Yu H; Zhou L; Zhao Y; Zhong L; Zhu J; Liang G; Yang Y; Zheng Y; Yu L; Han G
Int J Antimicrob Agents; 2023 Jun; 61(6):106812. PubMed ID: 37037321
[TBL] [Abstract][Full Text] [Related]
12. Trough-guided Versus AUC/MIC-Guided Vancomycin Monitoring: A Cost Analysis.
Morales Junior R; Tiguman GMB; D'Amaro Juodinis V; Santos ICPF; Leite FS; Vercelino JG; de Lima BD; Barbosa LMG
Clin Ther; 2022 Sep; 44(9):e91-e96. PubMed ID: 36031477
[TBL] [Abstract][Full Text] [Related]
13. Cost-benefit analysis comparing trough, two-level AUC and Bayesian AUC dosing for vancomycin.
Lee BV; Fong G; Bolaris M; Neely M; Minejima E; Kang A; Lee G; Gong CL
Clin Microbiol Infect; 2021 Sep; 27(9):1346.e1-1346.e7. PubMed ID: 33221430
[TBL] [Abstract][Full Text] [Related]
14. Risk of Acute Kidney Injury Based on Vancomycin Target Trough Attainment Strategy: Area-Under-the-Curve-Guided Bayesian Software, Nomogram, or Trough-Guided Dosing.
Knight JM; Iso T; Perez KK; Swan JT; Janak CE; Ikwuagwu JO; Musick WL
Ann Pharmacother; 2024 Feb; 58(2):110-117. PubMed ID: 37144736
[TBL] [Abstract][Full Text] [Related]
15. Comparison of vancomycin area under the curve calculated based on Bayesian approach versus equation-based approach.
Lee E; Yu U; Park JI; Park SI
Int J Clin Pharmacol Ther; 2024 May; 62(5):204-212. PubMed ID: 38329916
[TBL] [Abstract][Full Text] [Related]
16. Review and Validation of Bayesian Dose-Optimizing Software and Equations for Calculation of the Vancomycin Area Under the Curve in Critically Ill Patients.
Turner RB; Kojiro K; Shephard EA; Won R; Chang E; Chan D; Elbarbry F
Pharmacotherapy; 2018 Dec; 38(12):1174-1183. PubMed ID: 30362592
[TBL] [Abstract][Full Text] [Related]
17. The Impact of AUC-Based Monitoring on Pharmacist-Directed Vancomycin Dose Adjustments in Complicated Methicillin-Resistant
Stoessel AM; Hale CM; Seabury RW; Miller CD; Steele JM
J Pharm Pract; 2019 Aug; 32(4):442-446. PubMed ID: 29554847
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the mathematical equation and trapezoidal approach for 24 h area under the plasma concentration-time curve calculation in patients who received intravenous vancomycin in an acute care setting.
Chanapiwat P; Paiboonvong T; Rattanaumpawan P; Montakantikul P
Pharmacol Res Perspect; 2023 Feb; 11(1):e01046. PubMed ID: 36588162
[TBL] [Abstract][Full Text] [Related]
19. Are vancomycin trough concentrations adequate for optimal dosing?
Neely MN; Youn G; Jones B; Jelliffe RW; Drusano GL; Rodvold KA; Lodise TP
Antimicrob Agents Chemother; 2014; 58(1):309-16. PubMed ID: 24165176
[TBL] [Abstract][Full Text] [Related]
20. VANCOmycin dose adjustments comparing trough levels to the ratio of the area under de curve to the minimum inhibitory concentration method using a BAYESian approach: A feasibility study.
Bilodeau V; Huot J; Perreault C; Haraoui LP; Delorme C; Poudrette J; Marsot A; Crevier B
J Clin Pharm Ther; 2022 Dec; 47(12):2335-2344. PubMed ID: 36461655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
